Purple Biotech Ltd (PPBT) FinancialsPPBTPurple Biotech Ltd

Evaluating the bottom line, Purple Biotech Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -110.64%, provide a clear picture of how effectively PPBT converts its operational activities into shareholder value.

In the context of the broader market, PPBT competes directly with industry leaders such as NSRX and NNVC. With a market capitalization of $2.18M, it holds a significant position in the sector. When comparing efficiency, PPBT's gross margin of N/A stands against NSRX's N/A and NNVC's N/A. Such benchmarking helps identify whether Purple Biotech Ltd is trading at a premium or discount relative to its financial performance.

The company has reported substantial losses, with a net income of -$23,545,000 in Q4 2025 and a GAAP EPS of -$0.09 for Q1 2026. However, it did show a positive net income of $441,000 in Q2 2026, indicating some recovery.